ARC Biotechnology LLC

Washington, DC · Biotech · Private

Targeted complement inhibitor therapeutic for myasthenia gravis, delivering complement inhibition to the neuromuscular junction

Grants
$1.0M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Targeted Therapy for Myasthenia Gravis$268,669
Federal grantDepartment of Health and Human Services · Phase I · Targeted Therapy for Myasthenia Gravis$501,508
Federal grantDepartment of Health and Human Services · Phase I · Targeted Therapy for Myasthenia Gravis$232,839
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1711SINOPIA BIOSCIENCES INC——
1712NEUROGT INC——
1713Lila Sciences——
1714ARC Biotechnology LLC——
1715ARMAGEN TECHNOLOGIES, INC.——
1716Metallomix, Inc—$2.1M
1717Mission Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.